Related Experiment Video
Updated: Jun 28, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks]
1Universitätsklinik für Anästhesiologie und Operative Intensivmedizin, Campus Virchow Klinikum und Campus Mitte, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
Insights
Patients with coronary stents need dual antiplatelet therapy. Withdrawing this medication for surgery risks fatal stent thrombosis, while continuing it risks bleeding. Acetylsalicylic acid has a low hemorrhagic risk and should only be stopped in select cases.
Area of Science:
- Cardiology
- Vascular Surgery
Background:
- Current guidelines recommend dual antiplatelet therapy for patients with coronary stents.
- Perioperative management requires balancing stent thrombosis risk against bleeding risk.
Purpose of the Study:
- To discuss the case of a fatal stent thrombosis.
- To review evidence on perioperative antiplatelet therapy management in stented patients.
Main Methods:
- Case report presentation.
- Literature review of current evidence on antiplatelet therapy interruption and continuation.
Main Results:
- Fatal stent thrombosis occurred after antithrombotic withdrawal.
- Hemorrhagic risk associated with acetylsalicylic acid for secondary prevention appears low.
- Discontinuation of acetylsalicylic acid is recommended only in selected cases.
Conclusions:
- Individualized risk assessment is crucial for managing antiplatelet therapy in stented patients undergoing surgery.
- Continued dual anticoagulation strategies warrant further discussion and investigation.
Abstract:
According to the present guidelines, patients with coronary stents are to be treated with dual antiplatelet therapy. In case surgery is needed, the risk of a fatal stent thrombosis by withdrawing antithrombotics needs to be balanced in each individual case against the risk of haemorrhagic complications on continued antiplatelet medication. We present a case of fatal stent thrombosis and discuss the current evidence regarding perioperative continuation and interruption of antiplatelet therapy for this patient population. In summary the haemorrhagic risk with acetylsalicylic acid for secondary prevention seems very low, and it should be discontinued only in selected cases. Continued dual anticoagulation concepts are also discussed.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Angina IV: Management
